Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 4 Multiple Myeloma 2 Cytokine Release Syndrome 2 Thrombocytosis 1 Thrombocytopenia 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Lymphoma, Follicular 1 Lymphoma 1 Castleman Disease 1 Burkitt Lymphoma 1 Anemia 1

Interventions

Cyclophosphamide 217 Rituximab 110 Etoposide 99 Peripheral Blood Stem Cell Transplantation 94 Vincristine 91 Filgrastim 91 Cytarabine 91 Methotrexate 90 fludarabine phosphate 85 Radiotherapy 67 Doxorubicin 67 Prednisone 66 Dexamethasone 57 Mycophenolic Acid 53 Cyclosporine 53 Whole-Body Irradiation 50 Busulfan 47 Melphalan 44 blinatumomab 43 Tacrolimus 42 fludarabine 41 Antilymphocyte Serum 40 Methylprednisolone 39 merphos 35 Calcium Dobesilate 34 Leucovorin 33 Granulocyte Colony-Stimulating Factor 30 Mercaptopurine 26 dexamethasone acetate 25 dexamethasone 21-phosphate 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × siltuximab × Lymphoid × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡